COMMUNIQUÉS West-GlobeNewswire

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
18/01/2019
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on January 18, 2019 HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its [...]
CTD Announces Partnership with United BioSource LLC (UBC) to support the Extension Protocol for its Phase I Clinical Trial in the United States
18/01/2019
Collaboration will allow patients in Extension Protocol to receive CTD’s drug intravenously at home ALACHUA, Fla., Jan. 18, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology [...]
TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer
18/01/2019
68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last therapy) Of 14 [...]
Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited
18/01/2019
Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 ( [...]
KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
18/01/2019
Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” CELEBRATION, Fla., Jan. 18, 2019 ( [...]
Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019
18/01/2019
CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today [...]
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
18/01/2019
Phase 1/2 study to be led by team at University of California, San Diego, with rights licensed to AVROBIO CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) a Phase 2 [...]
Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
18/01/2019
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. OTTAWA, Jan. 18, 2019 (GLOBE NEWSWIRE) -- [...]
CorVel Announces Promotion of Michael Combs to Chief Executive Officer
18/01/2019
IRVINE, Calif., Jan. 18, 2019 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), announced today that its Board of Directors has promoted the Company’s President, Michael Combs, to also serve as its Chief Executive [...]
Digirad Corporation Announces Appointment of Mitchell I. Quain to its Board of Directors
18/01/2019
SUWANEE, Ga., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ: DRAD) announced today the appointment of Mitchell I. Quain, 67, as a new independent director to its Board of Directors, effective immediately [...]
111, Inc. Announces Management and Board Changes
18/01/2019
SHANGHAI, China, Jan. 18, 2019 (GLOBE NEWSWIRE) -- 111, Inc. (NASDAQ: YI) (“111” or the “Company”), a leading integrated online and offline healthcare platform in China, today announced that Mr. Weihao Xu has resigned [...]
Biohit new-generation fecal immunochemical test (ColonView-FIT) is superior to traditional guaiac test in colorectal cancer screening
18/01/2019
Biohit Oyj Press release 18.01.2019 at 9.30 local time (EEST) Biohit ColonView test is a new-generation fecal immunochemical test (FIT) designed for detection of fecal occult blood (FOB) in subjects participating in [...]
Correction: Managers’ transactions
18/01/2019
Company announcement no.02/2019 Correction: Purchase of shares in Chr. Hansen Holding A/S For further information, please contact: Martin Riise, Head of Investor Relations, Tel: +45 53 39 22 50 Camilla Lercke, Head of [...]
Xbrane Biopharma announces acceptance of initiation of Xlucane clinical trial in the US
18/01/2019
Press release 2019-01-18 The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial with [...]
Managers’ transactions
18/01/2019
Company announcement no.02/2019 For further information, please contact: Martin Riise, Head of Investor Relations, Tel: +45 53 39 22 50 Camilla Lercke, Head of Media Relations, Tel: +45 53 39 23 84 About Chr. Hansen Chr [...]
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
18/01/2019
COPENHAGEN, Denmark, January 18, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the [...]
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
18/01/2019
LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug [...]
ERYTECH présente un poster sur l’étude en cours TRYbeCA-1 lors de la conférence annuelle ASCO-GI 2019
18/01/2019
LYON, France et CAMBRIDGE, Mass., 18 janv. 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant [...]
Sunesis Announces Pricing of $20 Million Offering of Securities
18/01/2019
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and ( [...]

Pages